927 results on '"Lederer, David J"'
Search Results
2. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma
- Author
-
Bacharier, Leonard B., Pavord, Ian D., Maspero, Jorge F., Jackson, Daniel J., Fiocchi, Alessandro G., Mao, Xuezhou, Jacob-Nara, Juby A., Deniz, Yamo, Laws, Elizabeth, Mannent, Leda P., Amin, Nikhil, Akinlade, Bolanle, Staudinger, Heribert W., Lederer, David J., and Hardin, Megan
- Published
- 2024
- Full Text
- View/download PDF
3. Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
- Author
-
Papi, Alberto, Castro, Mario, Corren, Jonathan, Pavord, Ian D., Tohda, Yuji, Altincatal, Arman, Pandit-Abid, Nami, Laws, Elizabeth, Akinlade, Bolanle, Mannent, Leda P., Gall, Rebecca, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J., Lederer, David J., and Hardin, Megan
- Published
- 2024
- Full Text
- View/download PDF
4. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study
- Author
-
Bacharier, Leonard B., Guilbert, Theresa W., Katelaris, Constance H., Deschildre, Antoine, Phipatanakul, Wanda, Liu, Dongfang, Altincatal, Arman, Mannent, Leda P., Amin, Nikhil, Laws, Elizabeth, Akinlade, Bolanle, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J., Lederer, David J., and Hardin, Megan
- Published
- 2024
- Full Text
- View/download PDF
5. Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroid (VOYAGE)
- Author
-
Maspero, Jorge F., Antila, Martti A., Deschildre, Antoine, Bacharier, Leonard B., Altincatal, Arman, Laws, Elizabeth, Mortensen, Eric, Radwan, Amr, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J., Lederer, David J., and Hardin, Megan
- Published
- 2024
- Full Text
- View/download PDF
6. Development of the Lung Transplant Frailty Scale (LT-FS)
- Author
-
Singer, Jonathan P., Christie, Jason D., Diamond, Joshua M., Anderson, Michaela A., Benvenuto, Luke A., Gao, Ying, Arcasoy, Selim M., Lederer, David J., Calabrese, Daniel, Wang, Ping, Hays, Steven R., Kukreja, Jasleen, Venado, Aida, Kolaitis, Nicholas A., Leard, Lorriana E., Shah, Rupal J., Kleinhenz, Mary Ellen, Golden, Jeffrey, Betancourt, Legna, Oyster, Michelle, Zaleski, Derek, Adler, Joe, Kalman, Laurel, Balar, Priya, Patel, Shreena, Medikonda, Nikhila, Koons, Brittany, Tevald, Michael, Covinsky, Kenneth E., Greenland, John R., and Katz, Patti K.
- Published
- 2023
- Full Text
- View/download PDF
7. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
- Author
-
Jackson, Daniel J., Bacharier, Leonard B., Phipatanakul, Wanda, Sher, Lawrence, Domingo, Christian, Papadopoulos, Nikolaos, Modena, Brian, Li, Ning, Xia, Changming, Kamal, Mohamed A., Dillon, Myles, Wolfe, Kelley, Gall, Rebecca, Amin, Nikhil, Mannent, Leda P., Laws, Elizabeth, Rowe, Paul J., Jacob-Nara, Juby A., Deniz, Yamo, Lederer, David J., Hardin, Megan, and Xu, Christine
- Published
- 2023
- Full Text
- View/download PDF
8. Subphenotypes of frailty in lung transplant candidates
- Author
-
Singer, Jonathan P., Calfee, Carolyn S., Delucchi, Kevin, Diamond, Joshua M., Anderson, Michaela A., Benvenuto, Luke A., Gao, Ying, Wang, Ping, Arcasoy, Selim M., Lederer, David J., Hays, Steven R., Kukreja, Jasleen, Venado, Aida, Kolaitis, Nicholas A., Leard, Lorianna E., Shah, Rupal J., Kleinhenz, Mary Ellen, Golden, Jeffrey, Betancourt, Legna, Oyster, Michelle, Brown, Melanie, Zaleski, Derek, Medikonda, Nikhila, Kalman, Laurel, Balar, Priya, Patel, Shreena, Calabrese, Daniel R., Greenland, John R., and Christie, Jason D.
- Published
- 2023
- Full Text
- View/download PDF
9. Skeletal muscle adiposity and outcomes in candidates for lung transplantation: a lung transplant body composition cohort study.
- Author
-
Anderson, Michaela R, Easthausen, Imaani, Gallagher, Grace, Udupa, Jayaram, Tong, Yubing, Torigian, Drew, Diamond, Joshua Matthew, Porteous, Mary Katherine, Palmer, Scott M, Snyder, Laurie D, Benvenuto, Luke, Aversa, Meghan, Arcasoy, Selim, Greenland, John R, Hays, Steven R, Kukreja, Jasleen, Cantu, Edward, Kim, John Shinn, Gallagher, Dympna, Baldwin, Matthew R, Barr, R Graham, Lederer, David J, Christie, Jason D, and Singer, Jonathan Paul
- Subjects
Abdominal Wall ,Thigh ,Muscle ,Skeletal ,Humans ,Lung Diseases ,Tomography ,X-Ray Computed ,Treatment Outcome ,Lung Transplantation ,Survival Rate ,Risk Assessment ,Cohort Studies ,Aged ,Middle Aged ,Waiting Lists ,Female ,Male ,Adiposity ,Walk Test ,clinical epidemiology ,imaging/CT MRI etc ,lung transplantation ,Transplantation ,Organ Transplantation ,Lung ,4.1 Discovery and preclinical testing of markers and technologies ,Detection ,screening and diagnosis ,imaging ,CT MRI etc ,Clinical Sciences ,Respiratory System - Abstract
CT measurement of body composition may improve lung transplant candidate selection. We assessed whether skeletal muscle adipose deposition on abdominal and thigh CT scans was associated with 6 min walk distance (6MWD) and wait-list survival in lung transplant candidates. Each ½-SD decrease in abdominal muscle attenuation (indicating greater lipid content) was associated with 14 m decrease in 6MWD (95% CI -20 to -8) and 20% increased risk of death or delisting (95% CI 10% to 40%). Each ½-standard deviation decrease in thigh muscle attenuation was associated with 15 m decrease in 6MWD (95% CI -21 to -10). CT imaging may improve candidate risk stratification.
- Published
- 2020
10. Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults The Multi-Ethnic Study of Atherosclerosis (MESA)
- Author
-
Kim, John S, Anderson, Michaela R, Podolanczuk, Anna J, Kawut, Steven M, Allison, Matthew A, Raghu, Ganesh, Hinckley-Stuckovsky, Karen, Hoffman, Eric A, Tracy, Russell P, Barr, R Graham, Lederer, David J, and Giles, Jon T
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Atherosclerosis ,Prevention ,Clinical Research ,Lung ,Aetiology ,2.1 Biological and endogenous factors ,Adipokines ,Adiponectin ,Aged ,Asymptomatic Diseases ,Body Mass Index ,Cohort Studies ,Female ,Humans ,Independent Living ,Leptin ,Lung Diseases ,Interstitial ,Male ,Middle Aged ,Obesity ,Resistin ,Smoking ,Tomography ,X-Ray Computed ,Vital Capacity ,adipokine ,chest imaging ,epidemiology ,interstitial lung disease ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundAdipokines have inflammatory and fibrotic properties that may be critical in interstitial lung disease (ILD). We examined associations of serum adipokine levels with CT imaging-based measures of subclinical ILD and lung function among community-dwelling adults.MethodsA subset of the original Multi-Ethnic Study of Atherosclerosis cohort (n = 1,968) had adiponectin, leptin, and resistin measured during follow-up visits (2002-2005). We used regression models to examine associations of adiponectin, leptin, and resistin levels with (1) high-attenuation areas (HAAs) from CT scans (2004-2005, n = 1,144), (2) interstitial lung abnormalities (ILAs) from CT scans (2010-2012, n = 872), and (3) FVC from spirometry (2004-2006, n = 1,446). We used -(1/HAA2), which we denoted with H, to model HAA as our outcome to meet model assumptions.ResultsHigher adiponectin was associated with lower HAA on CT imaging among adults with a BMI ≥ 25 kg/m2 (P for BMI interaction = .07). Leptin was more strongly associated with ILA among never smokers compared with ever smokers (P for smoking interaction = .004). For every 1-SD increment of log-transformed leptin, the percent predicted FVC was 3.8% lower (95% CI, -5.0 to -2.5). Higher serum resistin levels were associated with greater HAA on CT in a fully adjusted model. For every 1-SD increment of log-transformed resistin there was an increase in H of 14.8 (95% CI, 3.4-26.3).ConclusionsHigher adiponectin levels were associated with lower HAA on CT imaging among adults with a higher BMI. Higher leptin and resistin levels were associated with lower FVC and greater HAA, respectively.
- Published
- 2020
11. Efficiency in Lung Transplant Allocation Strategies
- Author
-
Zou, Jingjing, Lederer, David J., and Rabinowitz, Daniel
- Subjects
Statistics - Applications ,Statistics - Methodology - Abstract
Currently in the United States, lung transplantations are allocated to candidates according to the candidates' Lung Allocation Score (LAS). The LAS is an ad-hoc ranking system for patients' priorities of transplantation. The goal of this study is to develop a framework for improving patients' life expectancy over the LAS based on a comprehensive modeling of the lung transplantation waiting list. Patients and organs are modeled as arriving according to Poisson processes, patients' health status evolving a waiting time inhomogeneous Markov process until death or transplantation, with organ recipient's expected post-transplant residual life depending on waiting time and health status at transplantation. Under allocation rules satisfying minimal fairness requirements, the long-term average expected life converges, and its limit is a natural standard for comparing allocation strategies. Via the Hamilton-Jacobi-Bellman equations, upper bounds for the limiting average expected life are derived as a function of organ availability. Corresponding to each upper bound is an allocable set of (time, state) pairs at which patients would be optimally transplanted. The allocable set expands monotonically as organ availability increases, which motivates the development of an allocation strategy that leads to long-term expected life close to the upper bound. Simulation studies are conducted with model parameters estimated from national lung transplantation data. Results suggest that compared to the LAS, the proposed allocation strategy could provide a 7.7% increase in average total life. We further extended the results to the the allocation and matching of multiple organ types., Comment: 36 pages of main text, 10 figures
- Published
- 2018
12. Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study.
- Author
-
Anderson, Michaela R, Udupa, Jayaram K, Edwin, Ethan, Diamond, Joshua M, Singer, Jonathan P, Kukreja, Jasleen, Hays, Steven R, Greenland, John R, Ferrante, Anthony, Lippel, Matthew, Blue, Tatiana, McBurnie, Amika, Oyster, Michelle, Kalman, Laurel, Rushefski, Melanie, Wu, Caiyun, Pednekar, Gargi, Liu, Wen, Arcasoy, Selim, Sonett, Joshua, D'Ovidio, Frank, Bacchetta, Matthew, Newell, John D, Torigian, Drew, Cantu, Edward, Farber, Donna L, Giles, Jon T, Tong, Yubing, Palmer, Scott, Ware, Lorraine B, Hancock, Wayne W, Christie, Jason D, and Lederer, David J
- Subjects
Adipose Tissue ,Humans ,Obesity ,Tomography ,X-Ray Computed ,Organ Size ,Lung Transplantation ,Risk Assessment ,Prospective Studies ,Body Composition ,Aged ,Middle Aged ,Female ,Male ,Primary Graft Dysfunction ,adipose tissue ,inflammation ,lung transplantation ,obesity ,primary graft dysfunction ,Clinical Research ,Organ Transplantation ,Nutrition ,Rare Diseases ,Lung ,Transplantation ,Prevention ,Cancer ,Cardiovascular ,Cardiorespiratory Medicine and Haematology ,Surgery - Abstract
BackgroundObesity is associated with an increased risk of primary graft dysfunction (PGD) after lung transplantation. The contribution of specific adipose tissue depots is unknown.MethodsWe performed a prospective cohort study of adult lung transplant recipients at 4 U.S. transplant centers. We measured cross-sectional areas of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) on chest and abdominal computed tomography (CT) scans and indexed each measurement to height.2 We used logistic regression to examine the associations of adipose indices and adipose classes with grade 3 PGD at 48 or 72 hours, and Cox proportional hazards models to examine survival. We used latent class analyses to identify the patterns of adipose distribution. We examined the associations of adipose indices with plasma biomarkers of obesity and PGD.ResultsA total of 262 and 117 subjects had available chest CT scans and underwent protocol abdominal CT scans, respectively. In the adjusted models, a greater abdominal SAT index was associated with an increased risk of PGD (odds ratio 1.9, 95% CI 1.02-3.4, p = 0.04) but not with survival time. VAT indices were not associated with PGD risk or survival time. A greater abdominal SAT index correlated with greater pre- and post-transplant leptin (r = 0.61, p < 0.001, and r = 0.44, p < 0.001), pre-transplant IL-1RA (r = 0.25, p = 0.04), and post-transplant ICAM-1 (r = 0.25, p = 0.04). We identified 3 latent patterns of adiposity. The class defined by high thoracic and abdominal SAT had the greatest risk of PGD.ConclusionsSubcutaneous, but not visceral, adiposity is associated with an increased risk of PGD after lung transplantation.
- Published
- 2019
13. Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis.
- Author
-
Hobbs, Brian D, Putman, Rachel K, Araki, Tetsuro, Nishino, Mizuki, Gudmundsson, Gunnar, Gudnason, Vilmundur, Eiriksdottir, Gudny, Zilhao Nogueira, Nuno Rodrigues, Dupuis, Josée, Xu, Hanfei, O'Connor, George T, Manichaikul, Ani, Nguyen, Jennifer, Podolanczuk, Anna J, Madahar, Purnema, Rotter, Jerome I, Lederer, David J, Barr, R Graham, Rich, Stephen S, Ampleford, Elizabeth J, Ortega, Victor E, Peters, Stephen P, O'Neal, Wanda K, Newell, John D, Bleecker, Eugene R, Meyers, Deborah A, Allen, Richard J, Oldham, Justin M, Ma, Shwu-Fan, Noth, Imre, Jenkins, R Gisli, Maher, Toby M, Hubbard, Richard B, Wain, Louise V, Fingerlin, Tasha E, Schwartz, David A, Washko, George R, Rosas, Ivan O, Silverman, Edwin K, Hatabu, Hiroto, Cho, Michael H, and Hunninghake, Gary M
- Subjects
Humans ,Lung Diseases ,Interstitial ,Genetic Predisposition to Disease ,beta Karyopherins ,TATA Box Binding Protein-Like Proteins ,Case-Control Studies ,Polymorphism ,Single Nucleotide ,Aged ,Middle Aged ,Female ,Male ,Promoter Regions ,Genetic ,Idiopathic Pulmonary Fibrosis ,Genome-Wide Association Study ,Mucin-5B ,Genetic Loci ,SNP ,genetics ,genome-wide association study ,idiopathic pulmonary fibrosis ,interstitial lung abnormalities ,Genetics ,Lung ,Rare Diseases ,Chronic Obstructive Pulmonary Disease ,Clinical Research ,Prevention ,Human Genome ,Autoimmune Disease ,Aging ,2.1 Biological and endogenous factors ,Aetiology ,Respiratory ,Medical and Health Sciences ,Respiratory System - Abstract
Rationale: Interstitial lung abnormalities (ILAs) are associated with the highest genetic risk locus for idiopathic pulmonary fibrosis (IPF); however, the extent to which there are unique associations among individuals with ILAs or additional overlap with IPF is not known.Objectives: To perform a genome-wide association study (GWAS) of ILAs.Methods: ILAs and a subpleural-predominant subtype were assessed on chest computed tomography (CT) scans in the AGES (Age Gene/Environment Susceptibility), COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease [COPD]), Framingham Heart, ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points), MESA (Multi-Ethnic Study of Atherosclerosis), and SPIROMICS (Subpopulations and Intermediate Outcome Measures in COPD Study) studies. We performed a GWAS of ILAs in each cohort and combined the results using a meta-analysis. We assessed for overlapping associations in independent GWASs of IPF.Measurements and Main Results: Genome-wide genotyping data were available for 1,699 individuals with ILAs and 10,274 control subjects. The MUC5B (mucin 5B) promoter variant rs35705950 was significantly associated with both ILAs (P = 2.6 × 10-27) and subpleural ILAs (P = 1.6 × 10-29). We discovered novel genome-wide associations near IPO11 (rs6886640, P = 3.8 × 10-8) and FCF1P3 (rs73199442, P = 4.8 × 10-8) with ILAs, and near HTRE1 (rs7744971, P = 4.2 × 10-8) with subpleural-predominant ILAs. These novel associations were not associated with IPF. Among 12 previously reported IPF GWAS loci, five (DPP9, DSP, FAM13A, IVD, and MUC5B) were significantly associated (P
- Published
- 2019
14. A nonlinear relationship between visceral adipose tissue and frailty in adult lung transplant candidates.
- Author
-
Anderson, Michaela R, Kolaitis, Nicholas A, Gao, Ying, Kukreja, Jasleen, Greenland, John, Hays, Steven, Wolters, Paul, Golden, Jeff, Diamond, Joshua, Palmer, Scott, Arcasoy, Selim, Udupa, Jayaram, Christie, Jason D, Lederer, David J, and Singer, Jonathan P
- Subjects
Humans ,Tomography ,X-Ray Computed ,Body Mass Index ,Prognosis ,Lung Transplantation ,Incidence ,Risk Factors ,Follow-Up Studies ,Prospective Studies ,Cross-Sectional Studies ,Adult ,Aged ,Middle Aged ,United States ,Female ,Male ,Subcutaneous Fat ,Intra-Abdominal Fat ,Obesity ,Abdominal ,Frailty ,clinical research/practice ,lung transplantation/pulmonology ,obesity ,quality of life ,Lung ,Clinical Research ,Organ Transplantation ,Obesity ,Aging ,Prevention ,Transplantation ,clinical research ,practice ,lung transplantation ,pulmonology ,Medical and Health Sciences ,Surgery - Abstract
Frailty is a state of decreased physiologic reserve associated with poor outcomes before and after lung transplantation. Obesity, particularly central obesity characterized by excess proinflammatory visceral adipose tissue (VAT), is associated with incident frailty in middle-aged and older adults. The association between VAT and frailty in advanced lung disease, however, is unknown. In two, nonoverlapping multicenter cohorts of adults listed for lung transplantation, we measured VAT area on bioelectrical impedance assay (BIA) in one cohort and cross-sectional VAT and subcutaneous adipose tissue (SAT) areas on abdominal computed tomography (CT) in the other. We identified a nonlinear relationship between greater VAT by BIA and frailty. In fully adjusted piecewise regression models, every 20 cm2 increase in VAT area was associated with 50% increased odds of frailty in subjects with high VAT (95% CI 1.2-1.9, P
- Published
- 2019
15. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
- Author
-
Hanania, Nicola A., Castro, Mario, Bateman, Eric, Pavord, Ian D., Papi, Alberto, FitzGerald, J. Mark, Maspero, Jorge F., Katelaris, Constance H., Singh, Dave, Daizadeh, Nadia, Altincatal, Arman, Pandit-Abid, Nami, Soler, Xavier, Siddiqui, Shahid, Laws, Elizabeth, Jacob-Nara, Juby A., Rowe, Paul J., Lederer, David J., Hardin, Megan, and Deniz, Yamo
- Published
- 2023
- Full Text
- View/download PDF
16. AERIFY-1/-2: 2 phase 3 randomised controlled trials of itepekimab in former smokers with moderate-to-severe COPD
- Author
-
Rabe, Klaus F., primary, Martinez, Fernando J., additional, Bhatt, Surya P., additional, Kawayama, Tomotaka, additional, Cosio, Borja G., additional, Mroz, Robert M., additional, Boomsma, Maarten M., additional, Goulaouic, Helene, additional, Nivens, Michael C., additional, Djandji, Michel, additional, Soler, Xavier, additional, Liu, Ying, additional, Kosloski, Matthew P., additional, Xu, Christine R., additional, Amin, Nikhil, additional, Staudinger, Heribert, additional, Lederer, David J., additional, and Abdulai, Raolat M., additional
- Published
- 2024
- Full Text
- View/download PDF
17. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis
- Author
-
Moore, Camille, Blumhagen, Rachel Z, Yang, Ivana V, Walts, Avram, Powers, Julie, Walker, Tarik, Bishop, Makenna, Russell, Pamela, Vestal, Brian, Cardwell, Jonathan, Markin, Cheryl R, Mathai, Susan K, Schwarz, Marvin I, Steele, Mark P, Lee, Joyce, Brown, Kevin K, Loyd, James E, Crapo, James D, Silverman, Edwin K, Cho, Michael H, James, Judith A, Guthridge, Joel M, Cogan, Joy D, Kropski, Jonathan A, Swigris, Jeffrey J, Bair, Carol, Kim, Dong Soon, Ji, Wonjun, Kim, Hocheol, Song, Jin Woo, Maier, Lisa A, Pacheco, Karin A, Hirani, Nikhil, Poon, Azin S, Li, Feng, Jenkins, R Gisli, Braybrooke, Rebecca, Saini, Gauri, Maher, Toby M, Molyneaux, Philip L, Saunders, Peter, Zhang, Yingze, Gibson, Kevin F, Kass, Daniel J, Rojas, Mauricio, Sembrat, John, Wolters, Paul J, Collard, Harold R, Sundy, John S, O’Riordan, Thomas, Strek, Mary E, Noth, Imre, Ma, Shwu-Fan, Porteous, Mary K, Kreider, Maryl E, Patel, Namrata B, Inoue, Yoshikazu, Hirose, Masaki, Arai, Toru, Akagawa, Shinobu, Eickelberg, Oliver, Fernandez, Isis Enlil, Behr, Jürgen, Mogulkoc, Nesrin, Corte, Tamera J, Glaspole, Ian, Tomassetti, Sara, Ravaglia, Claudia, Poletti, Venerino, Crestani, Bruno, Borie, Raphael, Kannengiesser, Caroline, Parfrey, Helen, Fiddler, Christine, Rassl, Doris, Molina-Molina, Maria, Machahua, Carlos, Worboys, Ana Montes, Gudmundsson, Gunnar, Isaksson, Helgi J, Lederer, David J, Podolanczuk, Anna J, Montesi, Sydney B, Bendstrup, Elisabeth, Danchel, Vivi, Selman, Moises, Pardo, Annie, Henry, Michael T, Keane, Michael P, Doran, Peter, Vašáková, Martina, Sterclova, Martina, Ryerson, Christopher J, Wilcox, Pearce G, Okamoto, Tsukasa, Furusawa, Haruhiko, Miyazaki, Yasunari, Laurent, Geoffrey, Baltic, Svetlana, and Prele, Cecilia
- Subjects
Human Genome ,Autoimmune Disease ,Clinical Research ,Lung ,Genetics ,Rare Diseases ,2.1 Biological and endogenous factors ,Aetiology ,ATP-Binding Cassette Transporters ,Case-Control Studies ,Cellular Senescence ,DNA Helicases ,Exoribonucleases ,Female ,GTPase-Activating Proteins ,Genetic Predisposition to Disease ,Genetic Variation ,Genome-Wide Association Study ,High-Throughput Nucleotide Sequencing ,Host-Pathogen Interactions ,Humans ,Idiopathic Pulmonary Fibrosis ,Logistic Models ,Male ,Mucin-5B ,Promoter Regions ,Genetic ,Pulmonary Surfactant-Associated Protein A ,Pulmonary Surfactant-Associated Protein C ,RNA ,Sequence Analysis ,DNA ,Telomerase ,Telomere-Binding Proteins ,targeted resequencing ,idiopathic pulmonary fibrosis ,genetic variants ,rare variants ,disease risk alleles ,Medical and Health Sciences ,Respiratory System - Abstract
Rationale: Several common and rare genetic variants have been associated with idiopathic pulmonary fibrosis, a progressive fibrotic condition that is localized to the lung. Objectives: To develop an integrated understanding of the rare and common variants located in multiple loci that have been reported to contribute to the risk of disease. Methods: We performed deep targeted resequencing (3.69 Mb of DNA) in cases (n = 3,624) and control subjects (n = 4,442) across genes and regions previously associated with disease. We tested for associations between disease and 1) individual common variants via logistic regression and 2) groups of rare variants via sequence kernel association tests. Measurements and Main Results: Statistically significant common variant association signals occurred in all 10 of the regions chosen based on genome-wide association studies. The strongest risk variant is the MUC5B promoter variant rs35705950, with an odds ratio of 5.45 (95% confidence interval, 4.91-6.06) for one copy of the risk allele and 18.68 (95% confidence interval, 13.34-26.17) for two copies of the risk allele (P = 9.60 × 10-295). In addition to identifying for the first time that rare variation in FAM13A is associated with disease, we confirmed the role of rare variation in the TERT and RTEL1 gene regions in the risk of IPF, and found that the FAM13A and TERT regions have independent common and rare variant signals. Conclusions: A limited number of common and rare variants contribute to the risk of idiopathic pulmonary fibrosis in each of the resequencing regions, and these genetic variants focus on biological mechanisms of host defense and cell senescence.
- Published
- 2019
18. Associations of variants In the hexokinase 1 and interleukin 18 receptor regions with oxyhemoglobin saturation during sleep
- Author
-
Cade, Brian E, Chen, Han, Stilp, Adrienne M, Louie, Tin, Ancoli-Israel, Sonia, Arens, Raanan, Barfield, Richard, Below, Jennifer E, Cai, Jianwen, Conomos, Matthew P, Evans, Daniel S, Frazier-Wood, Alexis C, Gharib, Sina A, Gleason, Kevin J, Gottlieb, Daniel J, Hillman, David R, Johnson, W Craig, Lederer, David J, Lee, Jiwon, Loredo, Jose S, Mei, Hao, Mukherjee, Sutapa, Patel, Sanjay R, Post, Wendy S, Purcell, Shaun M, Ramos, Alberto R, Reid, Kathryn J, Rice, Ken, Shah, Neomi A, Sofer, Tamar, Taylor, Kent D, Thornton, Timothy A, Wang, Heming, Yaffe, Kristine, Zee, Phyllis C, Hanis, Craig L, Palmer, Lyle J, Rotter, Jerome I, Stone, Katie L, Tranah, Gregory J, Wilson, James G, Sunyaev, Shamil R, Laurie, Cathy C, Zhu, Xiaofeng, Saxena, Richa, Lin, Xihong, and Redline, Susan
- Subjects
Genetics ,Lung ,Sleep Research ,Clinical Research ,Human Genome ,2.1 Biological and endogenous factors ,Aetiology ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Cell Adhesion Molecules ,Neuronal ,Computational Biology ,Extracellular Matrix Proteins ,Female ,Gene Regulatory Networks ,Genetic Variation ,Genome-Wide Association Study ,Hexokinase ,Humans ,Hypoxia ,Interleukin-18 Receptor alpha Subunit ,Male ,Middle Aged ,NLR Family ,Pyrin Domain-Containing 3 Protein ,Nerve Tissue Proteins ,Oxygen ,Oxyhemoglobins ,Polymorphism ,Single Nucleotide ,Quantitative Trait Loci ,Reelin Protein ,Serine Endopeptidases ,Sleep ,Sleep Apnea Syndromes ,Young Adult ,Developmental Biology - Abstract
Sleep disordered breathing (SDB)-related overnight hypoxemia is associated with cardiometabolic disease and other comorbidities. Understanding the genetic bases for variations in nocturnal hypoxemia may help understand mechanisms influencing oxygenation and SDB-related mortality. We conducted genome-wide association tests across 10 cohorts and 4 populations to identify genetic variants associated with three correlated measures of overnight oxyhemoglobin saturation: average and minimum oxyhemoglobin saturation during sleep and the percent of sleep with oxyhemoglobin saturation under 90%. The discovery sample consisted of 8,326 individuals. Variants with p < 1 × 10(-6) were analyzed in a replication group of 14,410 individuals. We identified 3 significantly associated regions, including 2 regions in multi-ethnic analyses (2q12, 10q22). SNPs in the 2q12 region associated with minimum SpO2 (rs78136548 p = 2.70 × 10(-10)). SNPs at 10q22 were associated with all three traits including average SpO2 (rs72805692 p = 4.58 × 10(-8)). SNPs in both regions were associated in over 20,000 individuals and are supported by prior associations or functional evidence. Four additional significant regions were detected in secondary sex-stratified and combined discovery and replication analyses, including a region overlapping Reelin, a known marker of respiratory complex neurons.These are the first genome-wide significant findings reported for oxyhemoglobin saturation during sleep, a phenotype of high clinical interest. Our replicated associations with HK1 and IL18R1 suggest that variants in inflammatory pathways, such as the biologically-plausible NLRP3 inflammasome, may contribute to nocturnal hypoxemia.
- Published
- 2019
19. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial
- Author
-
Sher, Lawrence D., Wechsler, Michael E., Rabe, Klaus F., Maspero, Jorge F., Daizadeh, Nadia, Mao, Xuezhou, Ortiz, Benjamin, Mannent, Leda P., Laws, Elizabeth, Ruddy, Marcella, Pandit-Abid, Nami, Jacob-Nara, Juby A., Gall, Rebecca, Rowe, Paul J., Deniz, Yamo, Lederer, David J., and Hardin, Megan
- Published
- 2022
- Full Text
- View/download PDF
20. Frailty phenotypes and mortality after lung transplantation: A prospective cohort study.
- Author
-
Singer, Jonathan P, Diamond, Joshua M, Anderson, Michaela R, Katz, Patricia P, Covinsky, Ken, Oyster, Michelle, Blue, Tatiana, Soong, Allison, Kalman, Laurel, Shrestha, Pavan, Arcasoy, Selim M, Greenland, John R, Shah, Lori, Kukreja, Jasleen, Blumenthal, Nancy P, Easthausen, Imaani, Golden, Jeffrey A, McBurnie, Amika, Cantu, Ed, Sonett, Joshua, Hays, Steven, Robbins, Hilary, Raza, Kashif, Bacchetta, Matthew, Shah, Rupal J, D'Ovidio, Frank, Venado, Aida, Christie, Jason D, and Lederer, David J
- Subjects
Humans ,Lung Diseases ,Postoperative Complications ,Prognosis ,Lung Transplantation ,Severity of Illness Index ,Survival Rate ,Risk Factors ,Follow-Up Studies ,Prospective Studies ,Phenotype ,Quality of Life ,Aged ,Middle Aged ,Female ,Male ,Frailty ,clinical research/practice ,lung transplantation/pulmonology ,patient survival ,recipient selection ,Lung ,Organ Transplantation ,Clinical Research ,Transplantation ,Good Health and Well Being ,clinical research ,practice ,lung transplantation ,pulmonology ,Medical and Health Sciences ,Surgery - Abstract
Frailty is associated with increased mortality among lung transplant candidates. We sought to determine the association between frailty, as measured by the Short Physical Performance Battery (SPPB), and mortality after lung transplantation. In a multicenter prospective cohort study of adults who underwent lung transplantation, preoperative frailty was assessed with the SPPB (n = 318) and, in a secondary analysis, the Fried Frailty Phenotype (FFP; n = 299). We tested the association between preoperative frailty and mortality following lung transplantation with propensity score-adjusted Cox models. We calculated postestimation marginalized standardized risks for 1-year mortality by frailty status using multivariate logistic regression. SPPB frailty was associated with an increased risk of both 1- and 4-year mortality (adjusted hazard ratio [aHR]: 7.5; 95% confidence interval [CI]: 1.6-36.0 and aHR 3.8; 95%CI: 1.8-8.0, respectively). Each 1-point worsening in SPPB was associated with a 20% increased risk of death (aHR: 1.20; 95%CI: 1.08-1.33). Frail subjects had an absolute increased risk of death within the first year after transplantation of 12.2% (95%CI: 3.1%-21%). In secondary analyses, FFP frailty was associated with increased risk of death within the first postoperative year (aHR: 3.8; 95%CI: 1.1-13.2) but not over longer follow-up. Preoperative frailty is associated with an increased risk of death after lung transplantation.
- Published
- 2018
21. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey
- Author
-
Morisset, Julie, Johannson, Kerri A, Jones, Kirk D, Wolters, Paul J, Collard, Harold R, Walsh, Simon LF, Ley, Brett, Antoniou, Katerina M, Assayag, Deborah, Behr, Juergen, Bonella, Francesco, Brown, Kevin K, Collins, Bridget F, Cormier, Yvon, Corte, Tamera J, Costabel, Ulrich, Danoff, Sonye K, de Boer, Kaïssa, Fernandez Perez, Evans R, Flaherty, Kevin R, Goh, Nicole SL, Glaspole, Ian, Jones, Mark G, Kondoh, Yasuhiro, Kreuter, Michael, Lacasse, Yves, Lancaster, Lisa H, Lederer, David J, Lee, Joyce S, Maher, Toby M, Martinez, Fernando J, Meyer, Keith C, Mooney, Joshua J, Gall, Xavier Muñoz, Noble, Paul W, Noth, Imre, Oldham, Justin M, Alberto de Castro Pereira, Carlos, Poletti, Venerino, Selman, Moises, Spagnolo, Paolo, Renzoni, Elisabetta, Richeldi, Luca, Ryerson, Christopher J, Ryu, Jay H, Salisbury, Margaret L, Strek, Mary E, Tomassetti, Sara, Valeyre, Dominique, Vancheri, Carlo, Wijsenbeek, Marlies S, and Wuyts, Wim
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Detection ,screening and diagnosis ,4.1 Discovery and preclinical testing of markers and technologies ,Alveolitis ,Extrinsic Allergic ,Chronic Disease ,Consensus ,Delphi Technique ,Female ,Humans ,Internationality ,Male ,Surveys and Questionnaires ,hypersensitivity pneumonitis ,interstitial lung disease ,diagnosis ,Delphi ,HP Delphi Collaborators ,Diagnosis ,Hypersensitivity pneumonitis ,Interstitial Lung Disease ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
RationaleCurrent diagnosis of chronic hypersensitivity pneumonitis (cHP) involves considering a combination of clinical, radiological, and pathological information in multidisciplinary team discussions. However, this approach is highly variable with poor agreement between centers.ObjectivesWe aimed to identify diagnostic criteria for cHP that reach consensus among international experts.MethodsA 3-round modified Delphi survey was conducted between April and August 2017. Forty-five experts in interstitial lung disease from 14 countries participated in the online survey. Diagnostic items included in round 1 were generated using expert interviews and literature review. During rounds 1 and 2, experts rated the importance of each diagnostic item on a 5-point Likert scale. The a priori threshold of consensus was ≥ 75% of experts rating a diagnostic item as very important or important. In the third round, experts graded the items that met consensus as important and provided their level of diagnostic confidence for a series of clinical scenarios.Measurements and main resultsConsensus was achieved on 18 of the 40 diagnostic items. Among these, experts gave the highest level of importance to the identification of a causative antigen, time relation between exposure and disease, mosaic attenuation on chest imaging, and poorly formed non-necrotizing granulomas on pathology. In clinical scenarios, the diagnostic confidence of experts in cHP was heightened by the presence of these diagnostic items.ConclusionThis consensus-based approach for the diagnosis of cHP represents a first step towards the development of international guidelines for the diagnosis of cHP.
- Published
- 2018
22. Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction after Lung Transplant
- Author
-
Cantu, Edward, Diamond, Joshua M, Suzuki, Yoshikazu, Lasky, Jared, Schaufler, Christian, Lim, Brian, Shah, Rupal, Porteous, Mary, Lederer, David J, Kawut, Steven M, Palmer, Scott M, Snyder, Laurie D, Hartwig, Matthew G, Lama, Vibha N, Bhorade, Sangeeta, Bermudez, Christian, Crespo, Maria, McDyer, John, Wille, Keith, Orens, Jonathan, Shah, Pali D, Weinacker, Ann, Weill, David, Wilkes, David, Roe, David, Hage, Chadi, Ware, Lorraine B, Bellamy, Scarlett L, and Christie, Jason D
- Subjects
Transplantation ,Acute Respiratory Distress Syndrome ,Rare Diseases ,Organ Transplantation ,Lung ,Good Health and Well Being ,Adult ,Biomarkers ,Cause of Death ,Cohort Studies ,Consensus ,Female ,Graft Rejection ,Graft Survival ,Humans ,Kaplan-Meier Estimate ,Logistic Models ,Lung Transplantation ,Male ,Middle Aged ,Primary Graft Dysfunction ,Proportional Hazards Models ,Reproducibility of Results ,Retrospective Studies ,Risk Assessment ,Severity of Illness Index ,Survival Rate ,Time Factors ,United States ,Young Adult ,Lung Transplant Outcomes Group ,lung transplant ,lung transplant outcomes ,primary graft dysfunction ,Medical and Health Sciences ,Respiratory System - Abstract
RationalePrimary graft dysfunction (PGD) is a form of acute lung injury that occurs after lung transplantation. The definition of PGD was standardized in 2005. Since that time, clinical practice has evolved, and this definition is increasingly used as a primary endpoint for clinical trials; therefore, validation is warranted.ObjectivesWe sought to determine whether refinements to the 2005 consensus definition could further improve construct validity.MethodsData from the Lung Transplant Outcomes Group multicenter cohort were used to compare variations on the PGD definition, including alternate oxygenation thresholds, inclusion of additional severity groups, and effects of procedure type and mechanical ventilation. Convergent and divergent validity were compared for mortality prediction and concurrent lung injury biomarker discrimination.Measurements and main resultsA total of 1,179 subjects from 10 centers were enrolled from 2007 to 2012. Median length of follow-up was 4 years (interquartile range = 2.4-5.9). No mortality differences were noted between no PGD (grade 0) and mild PGD (grade 1). Significantly better mortality discrimination was evident for all definitions using later time points (48, 72, or 48-72 hours; P
- Published
- 2018
23. A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis
- Author
-
Rosas, Ivan O, Goldberg, Hilary J, Collard, Harold R, El-Chemaly, Souheil, Flaherty, Kevin, Hunninghake, Gary M, Lasky, Joseph A, Lederer, David J, Machado, Roberto, Martinez, Fernando J, Maurer, Rie, Teller, Danielle, Noth, Imre, Peters, Elizabeth, Raghu, Ganesh, Garcia, Joe GN, and Choi, Augustine MK
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Clinical Trials and Supportive Activities ,Clinical Research ,Autoimmune Disease ,Lung ,Rare Diseases ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Respiratory ,Administration ,Inhalation ,Adolescent ,Adult ,Aged ,Aged ,80 and over ,Carbon Monoxide ,Carboxyhemoglobin ,Double-Blind Method ,Female ,Forced Expiratory Volume ,Humans ,Idiopathic Pulmonary Fibrosis ,Male ,Middle Aged ,Patient Reported Outcome Measures ,Treatment Outcome ,Vital Capacity ,Young Adult ,carbon monoxide ,idiopathic pulmonary fibrosis ,inhaled therapy ,IPF ,MMP7 ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundPreclinical studies have demonstrated that low-dose carbon monoxide (CO) can abrogate experimental lung fibrosis. To test the therapeutic role of inhaled CO, we designed a clinical study in patients with idiopathic pulmonary fibrosis (IPF).MethodsWe conducted a multicenter, phase IIa, double-blinded, sham-controlled, clinical trial. Patients with IPF were randomized to treatment with inhaled CO at 100 to 200 parts per million or to inhaled 21% oxygen for 2 h daily, twice weekly, for 12 weeks. The primary study end point was the difference in change in matrix metalloproteinase-7 (MMP7) serum concentration after 12 weeks of treatment. Secondary end points included pulmonary function test measures, 6-min walk distance, rates of adverse events, acute exacerbation, hospitalization and death, and quality of life measures.ResultsFifty-eight subjects were randomized to treatment with inhaled CO (n = 29) or placebo (n = 29). Despite modest increases in CO blood levels, the change in MMP7 concentrations after 12 weeks of treatment did not significantly differ between the study arms (MMP7 difference at week 12, -0.90 ng/mL; 95% CI, -4.18 to 2.38 ng/mL). No differences were observed in physiologic measures, incidence of acute exacerbations, hospitalization, death, or patient-reported outcomes. Importantly, no differences in distribution of adverse events were noted between the treatment arms.ConclusionsInhaled CO is well tolerated and can be safely administered to patients with IPF in the ambulatory setting; however, inhaled CO did not result in significant changes in study end points. Our findings support testing the efficacy of inhaled therapies in future IPF clinical trials.Trial registryClinicalTrials.gov; No.: NCT01214187; URL: www.clinicaltrials.gov.
- Published
- 2018
24. Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.
- Author
-
Porteous, Mary K, Lee, James C, Lederer, David J, Palmer, Scott M, Cantu, Edward, Shah, Rupal J, Bellamy, Scarlett L, Lama, Vibha N, Bhorade, Sangeeta M, Crespo, Maria M, McDyer, John F, Wille, Keith M, Localio, A Russell, Orens, Jonathan B, Shah, Pali D, Weinacker, Ann B, Arcasoy, Selim, Wilkes, David S, Ware, Lorraine B, Christie, Jason D, Kawut, Steven M, Diamond, Joshua M, and Lung Transplant Outcomes Group
- Subjects
Lung Transplant Outcomes Group ,Lung ,Humans ,Hypertension ,Pulmonary ,Obesity ,Body Mass Index ,Prognosis ,Lung Transplantation ,Linear Models ,Logistic Models ,Risk Factors ,Retrospective Studies ,Time Factors ,Adult ,Middle Aged ,Tissue Donors ,United States ,Female ,Male ,Primary Graft Dysfunction ,Young Adult ,lung transplantation ,primary graft dysfunction ,pulmonary hypertension ,Rare Diseases ,Clinical Research ,Cardiovascular ,Transplantation ,Organ Transplantation ,Respiratory ,Good Health and Well Being - Abstract
RationalePulmonary hypertension from pulmonary arterial hypertension or parenchymal lung disease is associated with an increased risk for primary graft dysfunction after lung transplantation.ObjectiveWe evaluated the clinical determinants of severe primary graft dysfunction in pulmonary hypertension and developed and validated a prognostic model.MethodsWe conducted a retrospective cohort study of patients in the multicenter Lung Transplant Outcomes Group with pulmonary hypertension at transplant listing. Severe primary graft dysfunction was defined as PaO2/FiO2 ≤200 with allograft infiltrates at 48 or 72 hours after transplantation. Donor, recipient, and operative characteristics were evaluated in a multivariable explanatory model. A prognostic model derived using donor and recipient characteristics was then validated in a separate cohort.ResultsIn the explanatory model of 826 patients with pulmonary hypertension, donor tobacco smoke exposure, higher recipient body mass index, female sex, listing mean pulmonary artery pressure, right atrial pressure and creatinine at transplant, cardiopulmonary bypass use, transfusion volume, and reperfusion fraction of inspired oxygen were associated with primary graft dysfunction. Donor obesity was associated with a lower risk for primary graft dysfunction. Using a 20% threshold for elevated risk, the prognostic model had good negative predictive value in both derivation and validation cohorts (89.1% [95% confidence interval, 85.3-92.8] and 83.3% [95% confidence interval, 78.5-88.2], respectively), but low positive predictive value.ConclusionsSeveral recipient, donor, and operative characteristics were associated with severe primary graft dysfunction in patients with pulmonary hypertension, including several risk factors not identified in the overall transplant population. A prognostic model with donor and recipient clinical risk factors alone had low positive predictive value, but high negative predictive value, to rule out high risk for primary graft dysfunction.
- Published
- 2017
25. Blood eosinophils and FeNO are prognostic and predictive biomarkers in childhood asthma
- Author
-
Bacharier, Leonard B., primary, Pavord, Ian D., additional, Maspero, Jorge F., additional, Jackson, Daniel J., additional, Fiocchi, Alessandro G., additional, Mao, Xuezhou, additional, Jacob-Nara, Juby A., additional, Deniz, Yamo, additional, Laws, Elizabeth, additional, Mannent, Leda P., additional, Amin, Nikhil, additional, Akinlade, Bolanle, additional, Staudinger, Heribert W., additional, Lederer, David J., additional, and Hardin, Megan, additional
- Published
- 2024
- Full Text
- View/download PDF
26. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
- Author
-
Bacharier, Leonard B, primary, Maspero, Jorge F, additional, Katelaris, Constance H, additional, Fiocchi, Alessandro G, additional, Gagnon, Remi, additional, de Mir, Ines, additional, Guilbert, Theresa W, additional, Jackson, Daniel J, additional, Staudinger, Heribert W, additional, Laws, Elizabeth, additional, Mannent, Leda P, additional, Akinlade, Bolanle, additional, Maloney, Jennifer, additional, Tawo, Kelsey, additional, Khokhar, Faisal A, additional, Li, Ning, additional, Hardin, Megan, additional, Abdulai, Raolat M, additional, Lederer, David J, additional, Robinson, Lacey B, additional, Bacharier, Leonard B., additional, Maspero, Jorge F., additional, Katelaris, Constance H., additional, Fiocchi, Alessandro G., additional, De Mir, Ines, additional, Guilbert, Theresa W., additional, Jackson, Daniel J., additional, Staudinger, Heribert W., additional, Mannent, Leda P., additional, Khokhar, Faisal A., additional, Abdulai, Raolat M., additional, Lederer, David J., additional, and Robinson, Lacey B., additional
- Published
- 2023
- Full Text
- View/download PDF
27. EFFICIENCY IN LUNG TRANSPLANT ALLOCATION STRATEGIES
- Author
-
Zou, Jingjing, Lederer, David J., and Rabinowitz, Daniel
- Published
- 2020
28. Refining Low Physical Activity Measurement Improves Frailty Assessment in Advanced Lung Disease and Survivors of Critical Illness
- Author
-
Baldwin, Matthew R, Singer, Jonathan P, Huang, Debbie, Sell, Jessica, Gonzalez, Wendy C, Pollack, Lauren R, Maurer, Mathew S, D'Ovidio, Frank F, Bacchetta, Matthew, Sonett, Joshua R, Arcasoy, Selim M, Shah, Lori, Robbins, Hilary, Hays, Steven R, Kukreja, Jasleen, Greenland, John R, Shah, Rupal J, Leard, Lorriana, Morrell, Matthew, Gries, Cynthia, Katz, Patricia P, Christie, Jason D, Diamond, Joshua M, and Lederer, David J
- Subjects
Aging ,Clinical Research ,Lung ,Rehabilitation ,4.2 Evaluation of markers and technologies ,Detection ,screening and diagnosis ,7.1 Individual care needs ,Management of diseases and conditions ,Respiratory ,Aged ,Critical Illness ,Disability Evaluation ,Exercise ,Female ,Frailty ,Humans ,Intensive Care Units ,Kaplan-Meier Estimate ,Linear Models ,Lung Diseases ,Lung Transplantation ,Male ,Middle Aged ,Multivariate Analysis ,Prospective Studies ,Risk Assessment ,Severity of Illness Index ,Surveys and Questionnaires ,Survivors ,United States ,frailty ,motor activity ,disability ,lung transplantation ,critical illness ,Clinical Sciences ,Respiratory System - Abstract
RationaleThe frail phenotype has gained popularity as a clinically relevant measure in adults with advanced lung disease and in critical illness survivors. Because respiratory disease and chronic illness can greatly limit physical activity, the measurement of participation in traditional leisure time activities as a frailty component may lead to substantial misclassification of frailty in pulmonary and critical care patients.ObjectivesTo test and validate substituting the Duke Activity Status Index (DASI), a simple 12-item questionnaire, for the Minnesota Leisure Time Physical Activity (MLTA) questionnaire, a detailed questionnaire covering 18 leisure time activities, as the measure of low activity in the Fried frailty phenotype (FFP) instrument.MethodsIn separate multicenter prospective cohort studies of adults with advanced lung disease who were candidates for lung transplant and older survivors of acute respiratory failure, we assessed the FFP using either the MLTA or the DASI. For both the DASI and MLTA, we evaluated content validity by testing floor effects and construct validity through comparisons with conceptually related factors. We tested the predictive validity of substituting the DASI for the MLTA in the FFP assessment using Cox models to estimate associations between the FFP and delisting/death before transplant in those with advanced lung disease and 6-month mortality in older intensive care unit (ICU) survivors.ResultsAmong 618 adults with advanced lung disease and 130 older ICU survivors, the MLTA had a substantially greater floor effect than the DASI (42% vs. 1%, and 49% vs. 12%, respectively). The DASI correlated more strongly with strength and function measures than did the MLTA in both cohorts. In models adjusting for age, sex, comorbidities, and illness severity, substitution of the DASI for the MLTA led to stronger associations of the FFP with delisting/death in lung transplant candidates (FFP-MLTA hazard ratio [HR], 1.42; 95% confidence interval [CI], 0.55-3.65; FFP-DASI HR, 2.99; 95% CI, 1.03-8.65) and with mortality in older ICU survivors (FFP-MLTA HR, 2.68; 95% CI, 0.62-11.6; FFP-DASI HR, 5.71; 95% CI, 1.34-24.3).ConclusionsThe DASI improves the construct and predictive validity of frailty assessment in adults with advanced lung disease or recent critical illness. This simple questionnaire should replace the more complex MLTA in assessing the frailty phenotype in these populations.
- Published
- 2017
29. Lung Transplantation for Idiopathic Pulmonary Fibrosis
- Author
-
Lamas, Daniela J., Lederer, David J., Rounds, Sharon I.S., Series Editor, Dixon, Anne, Series Editor, Schnapp, Lynn M., Series Editor, Meyer, Keith C., editor, and Nathan, Steven D., editor
- Published
- 2019
- Full Text
- View/download PDF
30. Extended post ex-vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study
- Author
-
Leiva-Juárez, Miguel M., Urso, Andreacarola, Arango Tomás, Elisabet, Lederer, David J., Sanchez, Pablo, Griffith, Bartley, Davis, R. Duane, Daneshmand, Mani, Hartwig, Matthew, Cantu, Edward, Weyant, Michael J., Bermudez, Christian, D'Cunha, Jonathan, Machuca, Tiago, Wozniak, Thomas, Lynch, William, Nemeh, Hassan, Mulligan, Michael, Song, Tae, Jessen, Michael, Camp, Phillip C., Caldeira, Christiano, Whitson, Bryan, Kreisel, Daniel, Ramzy, Danny, and D'Ovidio, Frank
- Published
- 2020
- Full Text
- View/download PDF
31. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
- Author
-
Maher, Toby M, Corte, Tamera J, Fischer, Aryeh, Kreuter, Michael, Lederer, David J, Molina-Molina, Maria, Axmann, Judit, Kirchgaessler, Klaus-Uwe, Samara, Katerina, Gilberg, Frank, and Cottin, Vincent
- Published
- 2020
- Full Text
- View/download PDF
32. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial
- Author
-
Richeldi, Luca, Fernández Pérez, Evans R, Costabel, Ulrich, Albera, Carlo, Lederer, David J, Flaherty, Kevin R, Ettinger, Neil, Perez, Rafael, Scholand, Mary Beth, Goldin, Jonathan, Peony Yu, Kin-Hung, Neff, Thomas, Porter, Seth, Zhong, Ming, Gorina, Eduard, Kouchakji, Elias, and Raghu, Ganesh
- Published
- 2020
- Full Text
- View/download PDF
33. Frailty in Pulmonary and Critical Care Medicine.
- Author
-
Singer, Jonathan P, Lederer, David J, and Baldwin, Matthew R
- Subjects
Humans ,Lung Diseases ,Critical Illness ,Disability Evaluation ,Critical Care ,Health Status ,Body Composition ,Quality of Life ,Aged ,Frailty ,body composition ,disability ,frailty ,health-related quality of life ,mortality ,Aging ,Clinical Research ,Lung ,Prevention ,7.1 Individual care needs ,Aetiology ,2.1 Biological and endogenous factors ,Management of diseases and conditions ,Respiratory ,Good Health and Well Being - Abstract
Conceptualized first in the field of geriatrics, frailty is a syndrome characterized by a generalized vulnerability to stressors resulting from an accumulation of physiologic deficits across multiple interrelated systems. This accumulation of deficits results in poorer functional status and disability. Frailty is a "state of risk" for subsequent disproportionate declines in health status following new exposure to a physiologic stressor. Two predominant models have emerged to operationalize the measurement of frailty. The phenotype model defines frailty as a distinct clinical syndrome that includes conceptual domains such as strength, activity, wasting, and mobility. The cumulative deficit model defines frailty by enumerating the number of age-related things wrong with a person. The biological pathways driving frailty include chronic systemic inflammation, sarcopenia, and neuroendocrine dysregulation, among others. In adults with chronic lung disease, frailty is independently associated with more frequent exacerbations of lung disease, all-cause hospitalization, declines in functional status, and all-cause mortality. In addition, frail adults who become critically ill are more likely develop chronic critical illness or severe disability and have higher in-hospital and long-term mortality rates. The evaluation of frailty appears to provide important prognostic information above and beyond routinely collected measures in adults with chronic lung disease and the critically ill. The study of frailty in these populations, however, requires multipronged efforts aimed at refining clinical assessments, understanding the mechanisms, and developing therapeutic interventions.
- Published
- 2016
34. The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia
- Author
-
Diamond, Joshua M, Porteous, Mary K, Roberts, L Jackson, Wickersham, Nancy, Rushefski, Melanie, Kawut, Steven M, Shah, Rupal J, Cantu, Edward, Lederer, David J, Chatterjee, Shampa, Lama, Vibha N, Bhorade, Sangeeta, Crespo, Maria, McDyer, John, Wille, Keith, Orens, Jonathan, Weinacker, Ann, Arcasoy, Selim, Shah, Pali D, Wilkes, David S, Hage, Chadi, Palmer, Scott M, Snyder, Laurie, Calfee, Carolyn S, Ware, Lorraine B, Christie, Jason D, and Group, for the Lung Transplant Outcomes
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Tobacco Smoke and Health ,Tobacco ,Organ Transplantation ,Clinical Research ,Transplantation ,Respiratory ,Adult ,Biomarkers ,Female ,Follow-Up Studies ,Humans ,Hyperoxia ,Lipid Peroxidation ,Lung Transplantation ,Male ,Postoperative Complications ,Primary Graft Dysfunction ,Reperfusion Injury ,Retrospective Studies ,Smoking ,Time Factors ,Tissue Donors ,lung transplantation ,lipid peroxidation ,primary graft dysfunction ,F2-isoprostane ,isofuran ,ischemia reperfusion ,Lung Transplant Outcomes Group ,Cardiorespiratory Medicine and Haematology ,Surgery ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundDonor smoking history and higher fraction of inspired oxygen (FIO2) at reperfusion are associated with primary graft dysfunction (PGD) after lung transplantation. We hypothesized that oxidative injury biomarkers would be elevated in PGD, with higher levels associated with donor exposure to cigarette smoke and recipient hyperoxia at reperfusion.MethodsWe performed a nested case-control study of 72 lung transplant recipients from the Lung Transplant Outcomes Group cohort. Using mass spectroscopy, F2-isoprostanes and isofurans were measured in plasma collected after transplantation. Cases were defined in 2 ways: grade 3 PGD present at day 2 or day 3 after reperfusion (severe PGD) or any grade 3 PGD (any PGD).ResultsThere were 31 severe PGD cases with 41 controls and 35 any PGD cases with 37 controls. Plasma F2-isoprostane levels were higher in severe PGD cases compared with controls (28.6 pg/ml vs 19.8 pg/ml, p = 0.03). Plasma F2-isoprostane levels were higher in severe PGD cases compared with controls (29.6 pg/ml vs 19.0 pg/ml, p = 0.03) among patients reperfused with FIO2 >40%. Among recipients of lungs from donors with smoke exposure, plasma F2-isoprostane (38.2 pg/ml vs 22.5 pg/ml, p = 0.046) and isofuran (66.9 pg/ml vs 34.6 pg/ml, p = 0.046) levels were higher in severe PGD compared with control subjects.ConclusionsPlasma levels of lipid peroxidation products are higher in patients with severe PGD, in recipients of lungs from donors with smoke exposure, and in recipients exposed to higher Fio2 at reperfusion. Oxidative injury is an important mechanism of PGD and may be magnified by donor exposure to cigarette smoke and hyperoxia at reperfusion.
- Published
- 2016
35. Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE study
- Author
-
Bacharier, Leonard B., primary, Guilbert, Theresa W., additional, Katelaris, Constance H., additional, Deschildre, Antoine, additional, Phipatanakul, Wanda, additional, Liu, Dongfang, additional, Altincatal, Arman, additional, Mannent, Leda P., additional, Amin, Nikhil, additional, Laws, Elizabeth, additional, Akinlade, Bolanle, additional, Jacob-Nara, Juby A., additional, Deniz, Yamo, additional, Rowe, Paul J., additional, Lederer, David J., additional, and Hardin, Megan, additional
- Published
- 2023
- Full Text
- View/download PDF
36. Frailty Phenotypes, Disability, and Outcomes in Adult Candidates for Lung Transplantation
- Author
-
Singer, Jonathan P, Diamond, Joshua M, Gries, Cynthia J, McDonnough, Jamiela, Blanc, Paul D, Shah, Rupal, Dean, Monica Y, Hersh, Beverly, Wolters, Paul J, Tokman, Sofya, Arcasoy, Selim M, Ramphal, Kristy, Greenland, John R, Smith, Nancy, Heffernan, Pricilla, Shah, Lori, Shrestha, Pavan, Golden, Jeffrey A, Blumenthal, Nancy P, Huang, Debbie, Sonett, Joshua, Hays, Steven, Oyster, Michelle, Katz, Patricia P, Robbins, Hilary, Brown, Melanie, Leard, Lorriana E, Kukreja, Jasleen, Bacchetta, Matthew, Bush, Errol, D’Ovidio, Frank, Rushefski, Melanie, Raza, Kashif, Christie, Jason D, and Lederer, David J
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Lung ,Aging ,Organ Transplantation ,Clinical Research ,Transplantation ,Prevention ,Activities of Daily Living ,Aged ,Biomarkers ,Case-Control Studies ,Cohort Studies ,Disabled Persons ,Female ,Frail Elderly ,Geriatric Assessment ,Humans ,Insulin-Like Growth Factor I ,Interleukin-6 ,Leptin ,Lung Transplantation ,Male ,Middle Aged ,Phenotype ,Postoperative Complications ,Prevalence ,Prospective Studies ,Receptors ,Tumor Necrosis Factor ,Reproducibility of Results ,United States ,biomarker ,body composition ,disability ,frailty ,lung transplantation ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
RationaleFrailty is associated with morbidity and mortality in abdominal organ transplantation but has not been examined in lung transplantation.ObjectivesTo examine the construct and predictive validity of frailty phenotypes in lung transplant candidates.MethodsIn a multicenter prospective cohort, we measured frailty with the Fried Frailty Phenotype (FFP) and Short Physical Performance Battery (SPPB). We evaluated construct validity through comparisons with conceptually related factors. In a nested case-control study of frail and nonfrail subjects, we measured serum IL-6, tumor necrosis factor receptor 1, insulin-like growth factor I, and leptin. We estimated the association between frailty and disability using the Lung Transplant Valued Life Activities disability scale. We estimated the association between frailty and risk of delisting or death before transplant using multivariate logistic and Cox models, respectively.Measurements and main resultsOf 395 subjects, 354 completed FFP assessments and 262 completed SPPB assessments; 28% were frail by FFP (95% confidence interval [CI], 24-33%) and 10% based on the SPPB (95% CI, 7-14%). By either measure, frailty correlated more strongly with exercise capacity and grip strength than with lung function. Frail subjects tended to have higher plasma IL-6 and tumor necrosis factor receptor 1 and lower insulin-like growth factor I and leptin. Frailty by either measure was associated with greater disability. After adjusting for age, sex, diagnosis, and transplant center, both FFP and SPPB were associated with increased risk of delisting or death before lung transplant. For every 1-point worsening in score, hazard ratios were 1.30 (95% CI, 1.01-1.67) for FFP and 1.53 (95% CI, 1.19-1.59) for SPPB.ConclusionsFrailty is prevalent among lung transplant candidates and is independently associated with greater disability and an increased risk of delisting or death.
- Published
- 2015
37. Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis
- Author
-
Kreuter, Michael, Lederer, David J., Molina-Molina, Maria, Noth, Imre, Valenzuela, Claudia, Frankenstein, Lutz, Weycker, Derek, Atwood, Mark, Kirchgaessler, Klaus-Uwe, and Cottin, Vincent
- Published
- 2019
- Full Text
- View/download PDF
38. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis
- Author
-
Lederer, David J, Bradford, Williamson Z, Fagan, Elizabeth A, Glaspole, Ian, Glassberg, Marilyn K, Glasscock, Kenneth F, Kardatzke, David, King, Talmadge E, Lancaster, Lisa H, Nathan, Steven D, Pereira, Carlos A, Sahn, Steven A, Swigris, Jeffrey J, and Noble, Paul W
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Digestive Diseases ,Clinical Trials and Supportive Activities ,Autoimmune Disease ,Rare Diseases ,Lung ,Clinical Research ,Respiratory ,Adult ,Aged ,Aged ,80 and over ,Analysis of Variance ,Anti-Inflammatory Agents ,Non-Steroidal ,Female ,Humans ,Idiopathic Pulmonary Fibrosis ,Male ,Middle Aged ,Pyridones ,Reproducibility of Results ,Sensitivity and Specificity ,Treatment Outcome ,Vital Capacity ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
BackgroundFVC outcomes in clinical trials on idiopathic pulmonary fibrosis (IPF) can be substantially influenced by the analytic methodology and the handling of missing data. We conducted a series of sensitivity analyses to assess the robustness of the statistical finding and the stability of the estimate of the magnitude of treatment effect on the primary end point of FVC change in a phase 3 trial evaluating pirfenidone in adults with IPF.MethodsSource data included all 555 study participants randomized to treatment with pirfenidone or placebo in the Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) study. Sensitivity analyses were conducted to assess whether alternative statistical tests and methods for handling missing data influenced the observed magnitude of treatment effect on the primary end point of change from baseline to week 52 in FVC.ResultsThe distribution of FVC change at week 52 was systematically different between the two treatment groups and favored pirfenidone in each analysis. The method used to impute missing data due to death had a marked effect on the magnitude of change in FVC in both treatment groups; however, the magnitude of treatment benefit was generally consistent on a relative basis, with an approximate 50% reduction in FVC decline observed in the pirfenidone group in each analysis.ConclusionsOur results confirm the robustness of the statistical finding on the primary end point of change in FVC in the ASCEND trial and corroborate the estimated magnitude of the pirfenidone treatment effect in patients with IPF.Trial registryClinicalTrials.gov; No.: NCT01366209; URL: www.clinicaltrials.gov.
- Published
- 2015
39. Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
- Author
-
Santermans, Eva, Ford, Paul, Kreuter, Michael, Verbruggen, Nadia, Meyvisch, Paul, Wuyts, Wim A., Brown, Kevin K., Lederer, David J., Byrne, Adam J., Molyneaux, Philip L., Sivananthan, Arunon, Moor, Catharina C., Maher, Toby M., and Wijsenbeek, Marlies
- Published
- 2019
- Full Text
- View/download PDF
40. Body Composition and Mortality after Adult Lung Transplantation in the United States
- Author
-
Singer, Jonathan P, Peterson, Eric R, Snyder, Mark E, Katz, Patricia P, Golden, Jeffrey A, D’Ovidio, Frank, Bacchetta, Matthew, Sonett, Joshua R, Kukreja, Jasleen, Shah, Lori, Robbins, Hilary, Van Horn, Kristin, Shah, Rupal J, Diamond, Joshua M, Wickersham, Nancy, Sun, Li, Hays, Steven, Arcasoy, Selim M, Palmer, Scott M, Ware, Lorraine B, Christie, Jason D, and Lederer, David J
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Clinical Sciences ,Obesity ,Organ Transplantation ,Nutrition ,Lung ,Transplantation ,Evaluation of treatments and therapeutic interventions ,6.4 Surgery ,Cancer ,Metabolic and endocrine ,Oral and gastrointestinal ,Stroke ,Cardiovascular ,Good Health and Well Being ,Body Composition ,Body Mass Index ,Cohort Studies ,Cross-Sectional Studies ,Female ,Humans ,Leptin ,Lung Diseases ,Lung Transplantation ,Male ,Middle Aged ,Retrospective Studies ,Sarcopenia ,Survival Rate ,United States ,obesity ,sarcopenia ,adiposity ,leptin ,biomarker ,Medical and Health Sciences ,Respiratory System ,Cardiovascular medicine and haematology ,Clinical sciences - Abstract
RationaleObesity and underweight are contraindications to lung transplantation based on their associations with mortality in studies performed before implementation of the lung allocation score (LAS)-based organ allocation system in the United States Objectives: To determine the associations of body mass index (BMI) and plasma leptin levels with survival after lung transplantation.MethodsWe used multivariable-adjusted regression models to examine associations between BMI and 1-year mortality in 9,073 adults who underwent lung transplantation in the United States between May 2005 and June 2011, and plasma leptin and mortality in 599 Lung Transplant Outcomes Group study participants. We measured body fat and skeletal muscle mass using whole-body dual X-ray absorptiometry in 142 adult lung transplant candidates.Measurements and main resultsAdjusted mortality rates were similar among normal weight (BMI 18.5-24.9 kg/m(2)), overweight (BMI 25.0-29.9), and class I obese (BMI 30-34.9) transplant recipients. Underweight (BMI < 18.5) was associated with a 35% increased rate of death (95% confidence interval, 10-66%). Class II-III obesity (BMI ≥ 35 kg/m(2)) was associated with a nearly twofold increase in mortality (hazard ratio, 1.9; 95% confidence interval, 1.3-2.8). Higher leptin levels were associated with increased mortality after transplant surgery performed without cardiopulmonary bypass (P for interaction = 0.03). A BMI greater than or equal to 30 kg/m(2) was 26% sensitive and 97% specific for total body fat-defined obesity.ConclusionsA BMI of 30.0-34.9 kg/m(2) is not associated with 1-year mortality after lung transplantation in the LAS era, perhaps because of its low sensitivity for obesity. The association between leptin and mortality suggests the need to validate alternative methods to measure obesity in candidates for lung transplantation. A BMI greater than or equal to 30 kg/m(2) may no longer contraindicate lung transplantation.
- Published
- 2014
41. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study
- Author
-
Raghu, Ganesh, Flaherty, Kevin R, Lederer, David J, Lynch, David A, Colby, Thomas V, Myers, Jeffrey L, Groshong, Steve D, Larsen, Brandon T, Chung, Jonathan H, Steele, Mark P, Benzaquen, Sadia, Calero, Karel, Case, Amy H, Criner, Gerard J, Nathan, Steven D, Rai, Navdeep S, Ramaswamy, Murali, Hagmeyer, Lars, Davis, J Russell, Gauhar, Umair A, Pankratz, Daniel G, Choi, Yoonha, Huang, Jing, Walsh, P Sean, Neville, Hannah, Lofaro, Lori R, Barth, Neil M, Kennedy, Giulia C, Brown, Kevin K, and Martinez, Fernando J
- Published
- 2019
- Full Text
- View/download PDF
42. Surfactant protein A and D polymorphisms and methylprednisolone pharmacogenetics in donor lungs
- Author
-
Aramini, Beatrice, Geraghty, Patrick, Lederer, David J., Costa, Joseph, DiAngelo, Susan L., Floros, Joanna, and D'Ovidio, Frank
- Published
- 2019
- Full Text
- View/download PDF
43. Bidirectional transfer of Anelloviridae lineages between graft and host during lung transplantation
- Author
-
Abbas, Arwa A., Young, Jacque C., Clarke, Erik L., Diamond, Joshua M., Imai, Ize, Haas, Andrew R., Cantu, Edward, Lederer, David J., Meyer, Keith, Milewski, Rita K., Olthoff, Kim M., Shaked, Abraham, Christie, Jason D., Bushman, Frederic D., and Collman, Ronald G.
- Published
- 2019
- Full Text
- View/download PDF
44. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis
- Author
-
Nathan, Steven D., Costabel, Ulrich, Glaspole, Ian, Glassberg, Marilyn K., Lancaster, Lisa H., Lederer, David J., Pereira, Carlos A., Trzaskoma, Benjamin, Morgenthien, Elizabeth A., Limb, Susan L., and Wells, Athol U.
- Published
- 2019
- Full Text
- View/download PDF
45. Genetic Variation in the Prostaglandin E2 Pathway Is Associated with Primary Graft Dysfunction
- Author
-
Diamond, Joshua M, Akimova, Tatiana, Kazi, Altaf, Shah, Rupal J, Cantu, Edward, Feng, Rui, Levine, Matthew H, Kawut, Steven M, Meyer, Nuala J, Lee, James C, Hancock, Wayne W, Aplenc, Richard, Ware, Lorraine B, Palmer, Scott M, Bhorade, Sangeeta, Lama, Vibha N, Weinacker, Ann, Orens, Jonathan, Wille, Keith, Crespo, Maria, Lederer, David J, Arcasoy, Selim, Demissie, Ejigayehu, Christie, Jason D, and Group, for the Lung Transplant Outcomes
- Subjects
Rare Diseases ,Biotechnology ,Lung ,Genetics ,Prevention ,Clinical Research ,Human Genome ,Transplantation ,Organ Transplantation ,2.1 Biological and endogenous factors ,Aetiology ,Biomarkers ,Computational Biology ,Dinoprostone ,Female ,Genetic Association Studies ,Genetic Markers ,Genotype ,Genotyping Techniques ,Humans ,Intramolecular Oxidoreductases ,Lung Transplantation ,Male ,Middle Aged ,Polymorphism ,Single Nucleotide ,Primary Graft Dysfunction ,Prospective Studies ,Prostaglandin-E Synthases ,Receptors ,Prostaglandin E ,EP4 Subtype ,T-Lymphocytes ,Regulatory ,Lung Transplant Outcomes Group ,Medical and Health Sciences ,Respiratory System - Abstract
RationaleBiologic pathways with significant genetic conservation across human populations have been implicated in the pathogenesis of primary graft dysfunction (PGD). The evaluation of the role of recipient genetic variation in PGD has thus far been limited to single, candidate gene analyses.ObjectivesWe sought to identify genetic variants in lung transplant recipients that are responsible for increased risk of PGD using a two-phase large-scale genotyping approach.MethodsPhase 1 was a large-scale candidate gene association study of the multicenter, prospective Lung Transplant Outcomes Group cohort. Phase 2 included functional evaluation of selected variants and a bioinformatics screening of variants identified in phase 1.Measurements and main resultsAfter genetic data quality control, 680 lung transplant recipients were included in the analysis. In phase 1, a total of 17 variants were significantly associated with PGD, four of which were in the prostaglandin E2 family of genes. Among these were a coding variant in the gene encoding prostaglandin E2 synthase (PTGES2; P = 9.3 × 10(-5)) resulting in an arginine to histidine substitution at amino acid position 298, and three variants in a block containing the 5' promoter and first intron of the PTGER4 gene (encoding prostaglandin E2 receptor subtype 4; all P < 5 × 10(-5)). Functional evaluation in regulatory T cells identified that rs4434423A in the PTGER4 gene was associated with differential suppressive function of regulatory T cells.ConclusionsFurther research aimed at replication and additional functional insight into the role played by genetic variation in prostaglandin E2 synthetic and signaling pathways in PGD is warranted.
- Published
- 2014
46. Efficacy of dupilumab in patients with uncontrolled, moderate‐to‐severe asthma with fungal sensitization
- Author
-
Corren, Jonathan, primary, Hanania, Nicola A., additional, Busse, William W., additional, Sher, Lawrence D., additional, Altincatal, Arman, additional, Hardin, Megan, additional, Mannent, Leda P., additional, Amin, Nikhil, additional, Lederer, David J., additional, Soler, Xavier, additional, Jacob‐Nara, Juby A., additional, Rowe, Paul J., additional, and Deniz, Yamo, additional
- Published
- 2023
- Full Text
- View/download PDF
47. Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
- Author
-
Fiocchi, Alessandro G., primary, Phipatanakul, Wanda, additional, Zeiger, Robert S., additional, Durrani, Sandy R., additional, Cole, Jeremy, additional, Msihid, Jérôme, additional, Gall, Rebecca, additional, Jacob-Nara, Juby A., additional, Deniz, Yamo, additional, Rowe, Paul J., additional, Lederer, David J., additional, Hardin, Megan, additional, Zhang, Yi, additional, and Khan, Asif H., additional
- Published
- 2023
- Full Text
- View/download PDF
48. Dupilumab in Asia-Pacific patients with persistent asthma
- Author
-
Zhang, QingLing, primary, Nanshan, Zhong, additional, Dhooria, Sahajal, additional, Fu, Xiuhua, additional, Lin, Jie, additional, Li, Wen, additional, Laws, Elizabeth, additional, Mannent, Leda P., additional, Wang, Yi, additional, Li, Vivian, additional, Li, Anderson, additional, Hu, Chih-Chi, additional, Lederer, David J., additional, Abdulai, Raolat M., additional, Robinson, Lacey B., additional, and Zhang, QingLing, additional
- Published
- 2023
- Full Text
- View/download PDF
49. Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of Atherosclerosis
- Author
-
Madahar, Purnema, Duprez, Daniel A., Podolanczuk, Anna J., Bernstein, Elana J., Kawut, Steven M., Raghu, Ganesh, Barr, R. Graham, Gross, Myron D., Jacobs, David R., Jr., and Lederer, David J.
- Published
- 2018
- Full Text
- View/download PDF
50. Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals
- Author
-
Leisman, Daniel E., Harhay, Michael O., Lederer, David J., Abramson, Michael, Adjei, Alex A., Bakker, Jan, Ballas, Zuhair K., Barreiro, Esther, Bell, Scott C., Bellomo, Rinaldo, Bernstein, Jonathan A., Branson, Richard D., Brusasco, Vito, Chalmers, James D., Chokroverty, Sudhansu, Citerio, Giuseppe, Collop, Nancy A., Cooke, Colin R., Crapo, James D., Donaldson, Gavin, Fitzgerald, Dominic A., Grainger, Emma, Hale, Lauren, Herth, Felix J., Kochanek, Patrick M., Marks, Guy, Moorman, J. Randall, Ost, David E., Schatz, Michael, Sheikh, Aziz, Smyth, Alan R., Stewart, Iain, Stewart, Paul W., Swenson, Erik R., Szymusiak, Ronald, Teboul, Jean-Louis, Vincent, Jean-Louis, Wedzicha, Jadwiga A., and Maslove, David M.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.